NCT04999059View on ClinicalTrials.gov

Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201

TerminatedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

May 8, 2019

Primary Completion Date

August 16, 2023

Study Completion Date

August 16, 2023

Conditions
Fabry Disease
Interventions
OTHER

Safety and Efficacy Assessments

Safety evaluations, disease-specific assessments, and other assessments to monitor for long-term complications of gene therapy intervention.

Trial Locations (3)

Unknown

Royal Melbourne Hospital, Melbourne

Royal Perth Hospital, Perth

90420-020

Hospital de Clinicas de Porto Alegre, Porto Alegre

Sponsors

Lead Sponsor

AVROBIO
All Listed Sponsors
lead

AVROBIO

INDUSTRY

NCT04999059 - Long-Term Follow-up Study of Subjects With Fabry Disease Who Received Lentiviral Gene Therapy in Study AVRO-RD-01-201 | Biotech Hunter | Biotech Hunter